ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015

Jan 28, 2015, 06:00 ET from ImmunoCellular Therapeutics, Ltd.

LOS ANGELES, Jan. 28, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 2:00 pm ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City.     

To access the live audio webcast of the BIO CEO presentation, please log on through a link located in the Investors section of ImmunoCellular's website at www.imuc.com, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Contact:

ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com

Logo - http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO

 

SOURCE ImmunoCellular Therapeutics, Ltd.



RELATED LINKS

http://imuc.com